AstraZeneca has been granted a patent for antibody molecules that target the epidermal growth factor receptor (EGFR) and c-Met, with potential applications in cancer treatment. The patent details specific amino acid sequences for the antibody’s binding domains. GlobalData’s report on AstraZeneca gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on AstraZeneca, Personalized cancer vaccines was a key innovation area identified from patents. AstraZeneca's grant share as of July 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
Antibody molecules targeting egfr and c-met for cancer treatment
The granted patent US12065496B2 describes a novel antibody molecule designed to target two specific receptors: the epidermal growth factor receptor (EGFR) and c-Met. The antibody comprises two distinct antigen-binding domains, each with a heavy chain variable (VH) region and a light chain variable (VL) region characterized by specific complementarity determining regions (CDRs). The claims detail the amino acid sequences for these CDRs, allowing for variations in sequence identity ranging from 70% to 100% for both the VH and VL regions. Additionally, the antibody molecule can include modifications to the constant regions of the heavy and light chains to enhance stability and functionality, including the potential formation of disulfide bonds.
Furthermore, the patent outlines the creation of conjugates that link the antibody molecule to a drug, specifically a topoisomerase I inhibitor. The conjugates are designed to improve therapeutic efficacy by delivering the drug directly to target cells via the antibody. The claims also encompass pharmaceutical compositions containing these conjugates, as well as nucleic acids and expression vectors for producing the antibody molecules. The detailed specifications of the antibody structure and its conjugation to therapeutic agents highlight the potential for targeted cancer therapies, leveraging the dual receptor-binding capability of the antibody to enhance treatment outcomes.
To know more about GlobalData’s detailed insights on AstraZeneca, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
